StreetAlpha.app
Home › Stocks › GOSS

Gossamer Bio, Inc. (GOSS)

$10.72
▼ −4.54%
LAST CLOSE · NOV 20

Gossamer Bio is a San Diego biopharmaceutical company developing seralutinib, an inhaled drug for pulmonary hypertension. It last closed at $10.72 on Nov 20, down 4.54% on the day. The next earnings report for GOSS is expected around Tue, Mar 16, 2027, after the close. For the quarter ended Sep 2026, GOSS reported EPS of -$7.36 on revenue of $38.4M, with revenue up 189.1% from a year ago. Over its last 8 reports the stock moved an average of 10.1% the session after earnings.

AI Auto Pilots
Is GOSS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GOSS.

Key Stats

Last 12 months
Results
Revenue
$78.4M
+78.0% vs a year ago
Net income
−$125.1M
−159.5% margin
Free cash flow
−$156.0M
−199.0% margin
Operating margin
−140.0%
−$109.8M operating income
Valuation
Market cap
$65.6M
6.1M shares
P/E
–
Price to sales
0.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$51.2M
At Sep 30
Shareholder equity
−$122.8M
Shares outstanding
6.1M
At Nov 7
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $114.7M$114.7MFY2024FY2025: $48.5M$48.5MFY2025

From GOSS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 16
Estimated date · After the close
Reported EPS
-$7.36
Quarter ended Sep 2026
Year ago EPS
-$16.92
Same quarter last year
Revenue
$38.4M
+189.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.15Dec '24Mar 2025: -$0.16Mar '25Jun 2025: -$0.17Jun '25Sep 2025: -$16.92Sep '25Dec 2025: $42.58Dec '25Mar 2026: -$0.20Mar '26Jun 2026: -$0.08Jun '26Sep 2026: -$7.36Sep '26Latest -$7.36
Revenue by quarter
Dec 2024: $9.4MDec '24Mar 2025: $9.9MMar '25Jun 2025: $11.5MJun '25Sep 2025: $13.3MSep '25Dec 2025: $13.8MDec '25Mar 2026: $17.0MMar '26Jun 2026: $9.2MJun '26Sep 2026: $38.4MSep '26Latest $38.4M
How GOSS moved after its last 8 reports
Average move the session after a report ±10.1%
Nov 10, 2026After the close+3.6%
Jul 27, 2026After the close+2.9%
May 18, 2026Time not announced−43.3%
Mar 17, 2026After the close−8.0%
Nov 5, 2025After the close−2.5%
Aug 5, 2025After the close−8.3%
May 15, 2025After the close−0.9%
Mar 13, 2025After the close+11.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GOSSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GOSS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GOSS

Technical Analysis

GOSS · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 2% above its 20 day and 3% above its 50 day average. It is 148% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the swing low (Jul 24) at $10.57, and the nearest resistance the Pivot at $10.99.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 9.7%/day
Key levels
$309.6052 week high+2788.1%
$26.58200 day average+147.9%
$11.92100 day average+11.2%
$11.33Pivot R1+5.7%
$11.08Swing high (Oct 29)+3.4%
$10.99Pivot+2.5%
$10.72Last close
$10.57Swing low (Jul 24)−1.4%
$10.4920 day average−2.1%
$10.4050 day average−3.0%
$10.38Pivot S1−3.2%
$8.2952 week low−22.7%
Indicators
RSI (14)51.16Middle of its rangeNeutral
MACD0.24Above its signal lineBullish
Stochastic69.5Middle of its rangeNeutral
ADX (14)8.7No clear trend
Williams %R-42.7Oversold below −80, overbought above −20Neutral
CCI (20)55.9Oversold below −100, overbought above 100Neutral
Rate of change+9.7%Change over 10 sessionsBullish
ATR (14)$1.04Typical daily range, 9.7% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for GOSS

What happened before

See how GOSS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GOSS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GOSS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GOSSHow many large options trades hit GOSS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

GOSS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼72 buying vs 167 selling
  • ▼Held by funds -6177.8 pts
  • ▼Funds holding -95
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding76171−55.6%
In funds' top 1002−100.0%
Held by funds64.7%––
New / increased72 / 027 / 63−20.0%
Reduced / sold out3 / 16444 / 43+92.0%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GOSS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GOSS Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 19, 2025Sandra MilliganDirectorBuy26,050$1.92$50K
Every insider buy and sale for GOSS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See GOSS insider trades →

From SEC Form 4 filings by GOSS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GOSS is in one of them and how their past GOSS trades turned out.

GOSS in the AI portfolios
Loading…

GOSS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GOSS in an article yet. Here's the latest on the wider market.

GOSS in the news

About Gossamer Bio

Gossamer Bio is a biopharmaceutical company based in San Diego, California. It is developing seralutinib, an investigational inhaled medicine for pulmonary arterial hypertension and for pulmonary hypertension linked to interstitial lung disease. The drug is still in clinical trials and is not yet approved for sale. The company works with Chiesi on development and potential commercialization, and it focuses on people living with pulmonary hypertension.

Headquarters
San Diego, CA